PART 1

FOODBORNE and MICROBIAL TOXINS
PART 1  FOODBORNE and MICROBIAL TOXINS

I  Chemical Contamination and Additives  5  
by Cyrus Rangan, MD, FAAP

1  Food Contamination  5  
2  Food Additives and Sensitivities  22  

II  Staples and Spices  34  
3  Akee Fruit and Jamaican Vomiting Sickness  (Blighia sapida Köenig)  34  
4  Cinnamon  (Cinnamomum Species)  39  
5  Cyanogenic Foods  (Cassava, Fruit Kernels, and Cycad Seeds)  44  
6  Cycad Seeds and Chronic Neurologic Disease  (Cycas Species)  54  
7  Djenkol Bean  [Archidendron jiringa (Jack) I. C. Nielsen]  59  
8  Grass Pea and Neurolathyrism  (Lathyrus sativus L.)  62  
9  Nutmeg  (Myristica fragrans Houtt.)  67  
10  Pepper and Capsaicin  (Capsicum and Piper Species)  71  
11  Potatoes, Tomatoes, and Solanine Toxicity  (Solanum tuberosum L., Solanum lycopersicum L.)  77  
12  Rhubarb and Oxalosis  (Rheum Species)  84  

III  Microbes  89  

A  Bacteria  89  
by Cyrus Rangan, MD, FAAP

13  Bacillus cereus  89  
14  Campylobacter jejuni  96  

15  Clostridium botulinum  (Botulism)  103  
16  Clostridium perfringens  114  
17  Escherichia coli  120  
18  Listeria monocytogenes  133  
19  Salmonella  141  
20  Shigella Species  (Shiga Enterotoxins)  150  
21  Staphylococcus aureus  156  
22  Streptococcus Species  162  
23  Vibrio Species  167  
24  Yersinia enterocolitica  174  

B  Other Microbes  181  
25  Cyanobacteria  181  
26  Protozoa and Intestinal Parasites  191  
27  Gastrointestinal Viruses  202  

IV  Seafood  212  

28  Amnesic Shellfish Poisoning and Domoic Acid  212  
29  Azaspiracid Shellfish Poisoning and Azaspiracid Toxins  218  
30  Diarrhetic Shellfish Poisoning and Okadaic Acid  222  
31  Neurotoxic Shellfish Poisoning and Brevetoxins  227  
32  Paralytic Shellfish Poisoning and Saxitoxins  231  
33  Ciguatera Fish Poisoning and Ciguatoxins  238  
34  Puffer Fish Poisoning and Tetrodotoxin  247  
35  Red Whelk and Tetramine  253  
36  Scombroid Fish, Scombroid-toxin, and Histamine  256
Records of outbreaks of human illness caused by toxic contaminants in foods appeared at least several centuries BC, when mad honey poisoning was associated with an illness among troops under the command of the Greek historian and mercenary, Xenophon. One of the first recorded foodborne outbreaks of ergotism occurred in Limoges, France during the Capetian Dynasty in 994 AD. The ingestion of rye bread contaminated with ergot alkaloids during this epidemic caused the deaths of approximately 20,000–50,000 victims. Numerous episodes of ergotism have occurred throughout history. Although ergotism is a possible explanation for the bizarre behavior that occurred before and during the Salem Witch Trials of 1692, there is no definite evidence that ergotism was a contributing factor. In the 1950s, mining operations in the Toyama region of Japan released cadmium into the Jinzu River. The use of this water for drinking and for irrigation of nearby rice fields resulted in a disease called itai-itai (translation: “ouch-ouch”), manifest by osteoporosis and renal dysfunction primarily in middle-aged women. In the same decade, numerous neonates born near Minamata Bay, Japan, developed birth defects and neurological abnormalities after pregnant women were exposed to seafood contaminated by methyl mercury released into the bay from a local factory. A methyl mercury-based fungicide caused an outbreak of mercury poisoning in Iraq in 1971 after grain seeds treated with the fungicide were inadvertently used for food manufacturing instead of planting. Prominent outbreaks of illnesses associated with chemical contamination of cooking oils include tri-ortho-cresyl phosphate-induced neuropathy (Morocco, 1959), yusho (“rice oil disease,” Japan, 1968), yu-cheng (“oil disease,” Taiwan, 1979), toxic oil syndrome (Spain, 1981), and epidemic dropsy (India, 1998). Some contaminants are unavoidable in food manufacturing. In the United States, the Food and Drug Administration (FDA) imposes “Current Good Manufacturing Practices” (CGMP) on food manufacturers. These mandatory codes enable the FDA to cite food products as unfit if an unavoidable contaminant poses a risk of harm by violating a standard or action level for that unavoidable contaminant (e.g., aflatoxin). Food products are considered adulterated when concentrations of avoidable contaminants (e.g., pesticides) exceed established standards, sometimes prompting food recalls after sale and distribution.

Metal contaminants such as lead, mercury, arsenic, and cadmium come from factory emissions, mining operations, and metal-containing industrial products used in food production. Methyl mercury found in commercially sold seafood is deemed an unavoidable contaminant because contamination preexists in the raw material; therefore, the contamination does not result from food processing or distribution. Fish and shellfish acquire methyl mercury primarily from microorganisms that methylate environmental inorganic mercury compounds released primarily from industrial sources.
YUSHO and YU-CHENG

HISTORY

The first known case of yusho (rice oil disease) involved a 3-year-old girl in northern Kyushu, Japan, who had an acute onset of an acneiform rash (chloracne) in June, 1968. Her family members, followed by other familial clusters, presented to a single clinic with complaints of acneiform rash, hyperpigmentation, and eye discharge over the next 2 months. By January 1969, 325 cases were reported. After a small minority of patients initially identified rice oil as the causative agent of yusho, Kyushu University convened the Study Group for Yusho to investigate yusho; about 2,000 afflicted patients were subsequently identified. The clinical features of yusho included fatigue, headache, cough, abdominal pain, peripheral numbness, hepatomegaly, irregular menstrual cycles, nail deformities, and hypersecretion of sebaceous glands. A field survey of canned rice oil associated the disease with the use of “K Rice Oil” produced or shipped by the K Company on February 5-6, 1968. The yu-cheng epidemic involved over 2,000 individuals in Taiwan in 1979, when an accidental leakage of thermal exchange fluid resulted in the contamination of rice-bran oil with polychlorinated biphenyls (PCBs), dibenzofurans (PCDFs), and quaterphenyls (PCQs). The clinical features of yu-cheng and yusho were similar.

EXPOSURE

Source

Polychlorinated biphenyls (PCBs) and polychlorinated dibenzofurans (PCDFs) are thermal heat exchanger compounds used in food processing machinery. Leakage of these compounds into rice oils during manufacturing led to the yusho and yu-cheng outbreaks.

YUSHO

Epidemiological studies revealed that 95.7% ($p < 0.01$) of surveyed patients recalled consumption of rice oil from K Company in Western Japan. A case-control study revealed rice oil as the only associated etiologic factor, and a cohort study demonstrated a 64% risk of yusho in K rice oil consumers compared with no risk for nonexposed individuals. Food engineers confirmed the leakage of dielectric thermal exchange fluid (Kanechlor 400) containing PCBs into the rice oil. This contaminant contained PCB compounds, primarily tetra-chlorinated biphenyls. In 1969, the Study Group initially concluded that PCBs caused yusho. However, a lack of similar symptoms (besides chloracne) in PCB workers who had significantly higher tissue burdens (mean blood PCB level: 45 ppb) contradicted this conclusion. Furthermore, the dermatological lesions could not be reproduced in animals following the oral administration of PCB compounds or by Kanechlor 400, and the severity of the clinical features of yusho did not correlate to serum concentrations of PCB compounds. Therefore, other compounds (e.g., polychlorinated dibenzofurans) in the adulterated rice oil probably contributed to the development of yusho.

YU-CHENG

As with the yusho incident, the suspected causative agents of yu-cheng were PCDFs rather than PCBs. Contamination of the cooking oil occurred when PCBs used for the indirect heating of rice-bran oil leaked into the cooking oil. Repeated heating of the partially degraded PCBs produced PCDFs, as well as polychlorinated terphenyl and polychlorinated quaterphenyl compounds.

Food Processing

High temperatures (>200°C) in dielectric thermal exchange fluid during the deodorization step of oil refining contributed to the development of yusho and yu-cheng by degrading PCBs in the contaminated rice oil to PCDFs, PCDDs (polychlorinated dibenzo dioxins), and PCQs (polychlorinated quaterphenyls).

DOSE RESPONSE

Exposure to toxic contaminants in the rice oil from the yusho and yu-cheng epidemics was assessed by recording the lot numbers of purchased oil containers and comparison of the volume of oil purchased to the volume of oil remaining in the containers retrieved from affected households. Consumption of the contaminated rice oil by household members was estimated by proportional distribution to each family member. Positive relationships were observed between estimated individual oil consumption and incidences of yusho and yu-cheng. The mean concentrations of PCBs, polychlorinated quaterphenyls (PCQs), and PCDFs in five samples of contaminated cooking oil from the yu-cheng outbreak were 62 ppm, 20 ppm, and 0.14 ppm, respectively. The congeners of these compounds were similar in the cooking oils from these two outbreaks, but yu-cheng cooking oil
samples contained about 10% of the concentrations of these compounds found in cooking oil from the yusho incident along with three to four times lower PCQs/PCBs and PCDFs/PCBs ratios.

A cross-sectional study of 79 patients with documented yusho demonstrated a dose-response relationship between estimated consumption of contaminated rice oil and the symptoms of extremity numbness, coughing, expectoration, and the sensation of “elevated teeth.” These symptoms were evaluated by self-administered questionnaires. Symptoms failing to demonstrate a dose-response relationship to the estimated ingestion of contaminated rice oil included fatigue, eye discharge, fever, headache, dizziness, abdominal pain, swollen joints, menstrual irregularities, and alopecia. The estimated mean total intake of PCBs and PCDFs by yusho patients was about 633 mg and 3.4 mg, respectively, compared with 973 mg and 3.84 mg, respectively, for yu-cheng patients.19

CLINICAL RESPONSE

Animal studies confirm a strong association between high concentrations of PCBs (i.e., at least 60% chlorination) in diets and the incidence of hepatic carcinomas. However, no human studies have confirmed an association between PCB exposure and cancer. Therefore, PCBs are listed as probable human carcinogens by the International Agency for Research on Cancer (IARC) and the US Environmental Protection Agency (EPA).20

Yusho

Clinical features of this illness included fatigue, headache, cough, abdominal pain, peripheral numbness, hepatomegaly, irregular menstrual cycles, nail deformities, and sebaceous gland hypersecretion. The most common symptoms were eye discharge, hyperpigmentation (skin, mucous membranes, nails), acneform lesions, and weakness.19 Although the severity of these symptoms has decreased since the epidemic, follow-up studies of yusho survivors indicated that these symptoms persisted at least through 1993.21 The chloracne resolved relatively rapidly in children, but hyperpigmentation and hypertrichosis remained in some patients. Thirteen children born to yusho-affected mothers exhibited gray-brown skin discoloration at birth (“black babies,” “cola-colored babies”), but the discoloration spontaneously disappeared after several weeks. These babies exhibited no other symptoms consistent with yusho.22

Yu-cheng

The clinical features of yu-cheng and yusho are similar. Clinical findings include chloracne, hyperpigmentation, edema, weakness, vomiting, diarrhea, and hepatomegaly. The acneform eruptions were open comedones, papules, and pustules with dark heads distributed on the axilla, extremities, and external genitalia.23 Abnormalities in children of yu-cheng patients included low birth weights,24 prematurity, neurobehavioral changes such as delayed autonomic maturity,25 normal menarche with shortened menstrual cycles,26 abnormal reflexes, dysfunctions in visual recognition memory,27 and decreased intelligence scores.28 A 24-year follow-up study of yu-cheng victims demonstrated increased mortality from chronic liver disease and cirrhosis in men, but not in women.29 There was an increased incidence of systemic lupus erythematosus in exposed women in the later years. The mortality rates for cancers were similar between the exposed group and the background population.

DIAGNOSTIC TESTING

Analytical Methods

Gel permeation chromatography and high resolution gas chromatography/high resolution mass spectrometry detect and differentiate PCBs and PCDFs in oil samples and in human samples.30 Methods that utilize high performance liquid chromatography/mass spectroscopy (HPLC/MS) or high performance liquid chromatography/tandem mass spectrometry (HPLC/MS/MS) reliably detect the di-oleyl-phenyl amino propanediol ester (OOPAP) and other acylated phenyl amino propanediol derivatives (PAPs) in cooking oils.31 Methods to detect OOPAP in humans are not available.

Biomarkers

Rice oil from the yu-cheng epidemic contained approximately 3,000 ppm total PCBs. The mean blood concentration of PCBs in patients with chloracne and hyperpigmentation was in the range of approximately 5 ppm. There was a linear correlation between the severity of skin lesions and the total PCB concentrations in blood samples. Studies of human and animal subjects indicate that PCB concentrations in the range of 10–25 ppm cause similar skin abnormalities. Analysis of PCBs, PCDFs, and PCQs in contaminated rice-oil samples collected from factory cafeterias, school cafeterias, and the families of patients with yu-cheng ranged from 53–99 ppm, 0.18–0.40 ppm, and 25–53 ppm, respectively.32
Although the specific compound associated with yusho or yu-cheng remains unknown, PCDDs are more appropriate biological biomarkers for the severity of yusho and yu-cheng than other polychlorinated hydrocarbons because the presence of PCDDs in blood samples indicates exposure to these compounds or parent compounds as PCDDs do not occur in nature. These compounds persist in the blood for years. Clearance of PCDFs and PCBs in humans is nonlinear with faster elimination rates at higher concentrations. In blood samples from 3 yu-cheng patients, the whole blood elimination half-life of two persistent toxic congeners, 2,3,4,7,8-pentachlorodibenzofuran (PnCDF) and 1,2,3,4,7,8-hexachlorodibenzofuran (HxCDF) was approximately 21/2 years. The calculated blood elimination half-lives of the same PCDF congeners in yusho patients were more variable with median values near 10 years. In a follow-up study of 359 patients with yusho, the serum concentrations of PnCDF and PCBs remained significantly elevated over 35 years after the incident. The mean blood concentration of PnCDF in exposed patients was 177.50 pg/g lipids compared with 15.2 ± 8.9 pg/g lipids in the blood of healthy controls. The blood concentration of PnCDF in these patients correlated to some clinical symptoms of yusho including acneform eruption, comedones, oral pigmentation, constipation, numbness in the extremities, and body weight loss. Follow-up studies indicate that the blood elimination half-lives are shorter (i.e., about 1–5 years) for PCB congeners than PCDF congeners. Follow-up studies of blood samples from yusho patients 34 years after the incident indicate that PCDFs contribute about 65% of the remaining total toxic equivalents of dioxins (non-ortho PCBs, mono-ortho-PCBs, PCDDs, PCDFs). In particular, the mean concentration of some PCDF congeners were substantially higher than controls including 1,2,3,6,7,8-HxCDF (3.9 times), 1,2,3,4,7,8-HxCDF (12 times), and PnCDF (11.3 times). The blood samples from 165 yu-cheng patients collected 9–18 months after the onset of poisoning contained 10–720 ppb PCBs with a mean value of 38 ppb.

**Abnormalities**

Yusho and yu-cheng patients occasionally had mild elevation of serum hepatic aminotransferase concentrations, but results of most laboratory studies were within normal ranges. Hepatorenal function is usually normal.

**TREATMENT**

The treatment for yusho and yu-cheng is supportive. Dermatologic changes may persist for several months, and topical or systemic medications typically do not alter the time-course of these lesions. Yusho and yu-cheng patients require long-term follow-up for the development of liver dysfunction and malignancy.

**TOXIC OIL SYNDROME**

**HISTORY**

In the early 1980s, Spanish laws banned the importation of rapeseed oil for human consumption to protect the Spanish olive oil market. These laws required the denaturation of imported rapeseed oil with aniline, methylene blue, or castor oil as a means to make this imported oil unfit for human consumption. During late 1980 and early 1981, a substantial amount of aniline-denatured rapeseed oil imported from France was fraudulently diverted for human consumption through Catalonia. These oils were diluted with other edible oils, refined, and resold through a network of distributors and itinerant salesmen. Although these oils contained aniline, the toxic oil syndrome was apparently not associated with the aniline.

During the first quarter of 1981, an oil distributor based in the center of Madrid named RAELCA entered the illicit oil sales market with mixed aniline-denatured rapeseed oil. In March 1981, RAELCA purchased five lots of aniline-denatured rapeseed oil from two French food oil companies, and they shipped three lots to the ITH oil refinery in Seville. The other two lots went to the Danesa Bau refinery in Madrid. Although the denatured oils were intended for industrial use, roadside vendors sold the oils as “olive oil” to residents over a 2-month period. Most of the cases of toxic oil syndrome appeared in the period from May to August 1981. Figure 1.1 displays the number of cases of toxic oil syndrome diagnosed in 1981. Epidemiological studies concluded that the ITH oil refinery was the point source for the epidemic.

**EXPOSURE**

**Source**

The exact causal agent in the contaminated oil involved with toxic oil syndrome remains unknown, in part, because of the many potential toxins in denatured aniline compounds associated with this illness. In a study of toxic oil syndrome-associated oils, fractionation of
Food Processing

In contrast to other illicit rapeseed oil distributors, RAELCA mixed the denatured rapeseed oil with other oils after the refining process. All other illicit refiners of denatured rapeseed oil in Catalonia mixed the denatured and edible oils before refining the adulterated oils. The processing of the fraudulently diverted rapeseed oil probably contributed to the formation of toxic compounds in the oil. High temperatures during deodorization catalyzed the reaction of 2% aniline with triglycerides in the rapeseed oil associated with toxic oil syndrome.\(^4\) In experimental studies, the yield of 3-(N-phenylamino)-1,2-propanediol (PAP) esters in toxic oil syndrome is highest at 250–300°C (~480–570°F), similar to those temperatures achieved during the deodorizing step of oil refining.\(^4\) These studies indicate that the heating of denatured oil samples stored for 3 weeks yields higher concentrations of potentially toxic PAP esters compared with samples stored for 1 week. Distillation times did not significantly affect the formation of fatty acid anilide compounds. The development of toxic oil syndrome following the ingestion of denatured rapeseed oil stored for about 1 year suggests that the toxic compounds in these contaminated cooking oils are stable for at least 1 year.\(^4\)

DOSE RESPONSE

Dose response in toxic oil syndrome was evaluated by a case control study known as the “Toxi-Epi Study,” which followed sales and distribution chains of the fraudulently distributed industrial oil sold as edible cooking oil using the chemical markers, oleyl-anilide and di-oleyl-3-phenylprop-1,2-propanediol (OOPAP). The content of these compounds varied several fold in different samples of contaminated cooking oil. Cooking oil containers with a characteristic shape purchased by residents were traced back to the ITH oil refinery in Seville in southern Spain. Analytical studies showed a linear statistical correlation between the concentration of the chemical markers detected in the refinery’s oil and the log of the odds ratio for dose-response.\(^5\) Rapeseed oil concentrations of oleyl-anilide and OOPAP traced to this plant were 1900 ppm and 150 ppm, respectively.

CLINICAL RESPONSE

The first cases of toxic oil syndrome were reported on May 1, 1981 in central and northwestern Spain. Initial epidemiological studies demonstrated clustering in incidence and mortality for toxic oil syndrome in households distributed along transportation routes throughout the affected regions. In July 1981, Spanish health officials announced that a fraudulently distributed, industrial oil sold as edible cooking oil was the etiology of this illness, initially termed pneumonic paralytic eosinophilic syndrome.\(^5\) The Spanish government subsequently initiated a consumer exchange program for olive oil, and they stockpiled the contaminated oil for further study.\(^5\) In 1983, the World Health Organization named the illness toxic oil syndrome.\(^5\) The official census originally consisted of records of patients with clinically suspected toxic oil syndrome that did not necessarily fulfill the case definition of the 1981 Spanish
Clinical Commission. A 1987 review of these records by the World Health Organization Regional Office for Europe Scientific Committee for the Investigation of the Toxic Oil Syndrome indicated that about 20,000 people were affected with over 10,000 hospitalizations. Although during the first few years about 300 patients died of toxic oil syndrome, the overall mortality of the cohort with toxic oil syndrome was not elevated after the first year of the epidemic when compared with the general Spanish population.

Toxic oil syndrome is a progressive multisystemic disease with three distinct clinical phases (acute, intermediate, chronic). The average latency period was about 4 to 7 days after the ingestion of the contaminated oil with a maximum of about 10 days. The basic underlying pathological lesion is a nonnecrotizing vasculitis with associated thrombotic events. Common initial symptoms of toxic oil syndrome included fever, cough, dyspnea, and chest pain. Other acute symptoms included urticarial rash, pruritus, abdominal cramping, and headache. The differential diagnosis for toxic oil syndrome includes other autoimmune disorders such as eosinophilia-myalgia syndrome, eosinophilic fascitis, systemic sclerosis, scleroderma, and systemic lupus erythematosus. Porphyria cutanea tarda did not occur in these patients.

**Acute (Pulmonary)**

The characteristic manifestation of the acute phase is the development of noncardiogenic pulmonary edema with dyspnea, alveolar-interstitial infiltrates with or without pleural effusions, peripheral eosinophilia, fever, and rash. Most patients recovered from this early pulmonary phase of the illness. Deaths during this phase occurred from respiratory insufficiency initially from degeneration of type I and type II pneumocytes and later from thromboembolic complications. During the acute phase (i.e., first 2 months), the primary lesion occurs in the endothelium of multiple organs with the exception of the central nervous system. Severe myalgias and muscle cramps occur at the end of the acute phase.

**Intermediate (Thrombotic)**

About 60% of the patients with the acute phase progress to the intermediate phase that involved the development of sensory peripheral neuropathy along with intense myalgias, dermal induration, and weight loss. More serious complications during this phase began about 2 months after the onset of illness, including pulmonary hypertension and thromboembolism of large vessels. In severe cases, histological examination demonstrated proliferation of the intimal lining of the vessels along with fibrosis and thrombosis.

**Chronic (Neuromuscular)**

Approximately 2 months after the onset of the intermediate phase, the chronic phase of toxic oil syndrome began, characterized by sclerodermiform changes, motor neuropathy, musculoskeletal contractures, muscle wasting, myalgias, muscle cramps, weight loss, limited joint mobility, peripheral eosinophilia, hepatomegaly, pulmonary hypertension, and Sjögren syndrome. Some patients developed this chronic phase without experiencing the acute pneumonic phase. The most common persistent symptoms were cough and dyspnea with about 20% of affected patients developing reduction in the carbon monoxide diffusing capacity. Mortality in the chronic phase was primarily due to infectious complications of respiratory insufficiency secondary to neuromuscular weakness, thromboembolism, or pulmonary hypertension with cor pulmonale. A minority of toxic oil syndrome patients developed severe pulmonary arterial hypertension during exercise over 20 years after exposure.

Long-term follow-up studies of survivors suggest reduction in the quality of life of these patients with elevated rates of depression (odds ratio [OR] = 9.66), functional disabilities (OR = 4.74), and psychosocial disabilities (OR = 2.82). Mortality was high during the first year, with a significant decline in mortality rates in subsequent years. Most of the decline in mortality was observed in elderly populations; however, the mortality rate in women <40 years of age increased as a result of complications from pulmonary hypertension. Concurrent clustering of incidence and mortality in toxic oil syndrome suggested that a genetic predisposition determines the severity of toxic oil syndrome. Linkage mapping of the human genome revealed increased mortality in patients with a chromosome 6-associated risk factor for the HLA-DR2 phenotype. Studies in enzyme mechanics implicate a role for impaired hepatic acetylation in mediating individual susceptibilities to toxic oil syndrome.

**DIAGNOSTIC TESTING**

**Analytical Methods**

Analytical methods to identify and quantify OOPAP and other PAPs in contaminated cooking oil samples include high performance liquid chromatography/atmospheric pressure ionization tandem mass spectrometry (HPLC/API/MS/MS) and HPLC/MS.

**Biomarkers**

The analysis of contaminated oil was complicated by poor identification markers on cooking oil bottles during therapy.

---

**PART 1 FOODBORNE and MICROBIAL TOXINS**
the recall process. Two case control studies suggested a
dose-related association between the presence of three
fatty acid anilide compounds (oleyl, linoleyl, palmityl)
and the risk of developing toxic oil syndrome. Of
these fatty acid anilide compounds, oleyl anilide occurred
in the highest concentration. Subsequent analyses
suggested that 3-(N-phenylamino)-1,2-propanediol
(DEPAP), a by-product of the same reaction of aniline
with triglycerides, is an equally sensitive and a more
specific biomarker of toxic oil syndrome than fatty
anilide compounds. Animal studies suggest that the
liver converts fatty acid mono- and diesters of 3-(N-
phenylimino)propane-1,2-diol to 3-(4′-hydroxyphenyl-
amino)-propane-1,2-diol, which generates the
electrophilic metabolite quinoneimine intermediate-2
(QI-2). However, the specific chemical causing toxic
oil syndrome has not been identified.

Abnormalities

Laboratory changes associated with toxic oil syndrome
include peripheral eosinophilia, hypertriglyceridemia,
and coagulation disorders in patients with liver involve-
ment. Analytical studies of toxic oil syndrome patients
demonstrate eosinophilia and a high concentration of
mRNA for T-helper-2 cytokines, IL-4 and IL-5, in the
lungs. Antemortem sera from fatal cases of toxic oil
syndrome also contained elevated serum IL-2R and
total IgE concentrations along with a high frequency of
HLA-DR2 on chromosome 6. The sinus and atrioven-
tricular nodes may exhibit dense fibrosis, hemorrhages,
or cystic degeneration similar to findings in scleroderma
and systemic lupus erythematosus. Coronary arteries
may exhibit focal fibromuscular dysplasia and cystic
myointimal degeneration with embolization. Histopath-
ological analyses show lymphocytic inflammatory lesions
of coronary arteries and the cardiac conduction system,
similar to the findings in eosinophilia-myalgia syndrome.
Cardiac lesions associated with eosinophilia-myalgia
syndrome, however, are distinguished by cytotoxic T-
cells directed against cardiac neural structures and sinus
nodal myocytes, whereas toxic oil syndrome cardiac
lesions are characterized by a prominence of B cells and
T-helper cells.

Chest x-ray demonstrates an interstitial-alveolar
pattern with progression to acute respiratory distress
syndrome (adult respiratory distress syndrome or
ARDS) in the acute phase of toxic oil syndrome. Eosin-
ophilia is a universal finding in toxic oil syndrome
patients. Hypoxemia, respiratory alkalosis, and an
increased alveolar-arterial oxygen gradient (A-a gradi-
et) as determined by arterial blood gases are common
in patients with severe toxic oil syndrome-induced non-
cardiogenic pulmonary edema during the acute phase.

TREATMENT

During the acute phase, respiratory compromise from
ARDS is the most serious complication of toxic oil
syndrome. Patients with toxic oil syndrome are also at
increased risk of cardiovascular disease that may mani-
fest several years after exposure. Echocardiography,
cholesterol screening, and weight management are effec-
tive tools for the screening and detection of cardiovas-
cular sequelae in patients with toxic oil syndrome. Long-term neuromuscular and articular complaints are
prominent, and abnormalities are treated symptomati-
cally. Patients should be monitored for the prominent
risk factors most closely associated with early mortality: female <40 years old, liver disease, pulmonary hyperten-
sion, frequent pulmonary infections, motor neuropathy,
and eosinophilia.

EPIDEMIC DROPSY

HISTORY

Although the first of several epidemics of epidemic
dropsy was documented in 1877 in Calcutta, the most
prominent epidemic dropsy epidemic occurred in Delhi,
India during August, 1998. The Indian Ministry of
Health received over 2,552 reports of poisoning with 65
deaths from August to October 1998. The incidence of
epidemic dropsy was higher in lower socioeconomic
groups, probably as a result of purchasing less expen-
sive, loosely packaged mustard oil from roadside
vendors. Epidemic dropsy (argemone toxicity) is char-
acterized by the pathological accumulation of lymph
throughout the body along with gastrointestinal distress,
cramps and myalgias, sarcoïd-like skin lesions, myalgias,
paresthesias, and painful edema of the lower extremities.

EXPOSURE

Argemone oil (Katkar oil) mixed with mustard oil and
ghee (clarified butter) caused epidemic dropsy out-
breaks in India, South Africa, and Nepal. Argemone
mexicana L. (Mexican prickly poppy, Satyanashi
[translation: devastating], Papaveraceae) is an invasive
weed with a yellow flower similar to the mustard flower
(� Brassica nigra (L.) W.D.J. Koch). Indian mustard oil
merchants commonly remark to public health officials that argemone seeds are inadvertently harvested with mustard seeds because they thrive in similar climates, with potentially overlapping harvests (Mustard—February/March; Argemone—April/May). However, the canopy-like structure of the mustard plant does not permit concurrent growth of other plants in the same fields; therefore, mustard seeds are generally harvested in February, leading to the widely accepted theory that adulterations of mustard oil with argemone oil are intentional.

Argemone oil contains two toxic alkaloids: dihydrosanguinarine (CAS RN: 3606-45-9, C_{20}H_{15}NO_{4}) and much smaller amounts of sanguinarine (CAS RN: 2447-54-3, C_{20}H_{14}NO_{4}). Although the concentration of dihydrosanguinarine in argemone oil is greater than sanguinarine, the toxicity of the latter compound is greater.

The names originate from the bloodroot (Sanguinaria canadensis L.), which is the original source of this alkaloid. These alkaloids are benzophenanthidine derivatives of glycosides that cause increased permeability of blood vessels, particularly in the heart, liver, eyes, gastrointestinal tract, and kidneys. Figure 1.2 and Figure 1.3 demonstrate the chemical structure of dihydrosanguinarine and sanguinarine, respectively.

The exact mechanism of toxicity of epidemic dropsy is unknown. Sanguinarine and dihydrosanguinarine accumulate in the gastrointestinal tract, serum, and tissues after binding tightly to plasma proteins. Potentially these toxic alkaloids cause damage by binding to Na^+-K^+-ATPase, inactivating hepatic cytochrome P-450 enzymes, depleting hepatic glutathione, and disrupting carbohydrate metabolism. The latter effect inhibits active transport of glucose across intestinal villi, resulting in increased glycogenolysis and the formation of excess glucose-1-phosphate, pyruvate, and lactate. These processes lead to the formation of reactive oxygen species, causing oxidation of plasma proteins and lipids.

**Food Processing**

Mustard seeds are differentiated from the seeds of Argemone mexicana L. by physical appearance: mustards seeds are smooth and round; argemone seeds are creased with spiked edges. Batches of mustard seeds are visually inspected for argemone seeds during processing with the argemone seed discarded upon detection. The practice of sorting is painstaking and cost-prohibitive, as 1% adulteration of mustard oil by argemone oil is enough to cause symptoms. The early harvesting of mustard avoids the contamination of mustard oil by argemone seeds. The toxic alkaloids in argemone oil are heat-stable to 240°C (∼460°F). Consequently, consumers in endemic areas are advised to heat mustard oils to 240°C for at least 15 minutes to deactivate the toxic alkaloids present in argemone seeds.

**DOSE RESPONSE**

As little as 1% adulteration of cooking oil with argemone oil is probably sufficient to cause clinical toxicity. Because sanguinarine and dihydrosanguinarine accumulate in human tissue, toxicity can result from subacute, low-dose exposure.

**CLINICAL RESPONSE**

The clinical features of epidemic dropsy begin approximately 1–3 weeks after consumption of contaminated oil with a variety of symptoms including nausea, vomiting, diarrhea, bloating, anorexia, hyperplastic lesions in the mouth and other mucous membranes, erythematous rash with bluish mottling (erythrocyanosis), nodular sarcoid-like skin lesions or telangiectasias, bilateral glaucomatous findings, anemia, muscle tenderness, numbness, tingling, and painful bilateral pitting edema, particularly of the lower extremities. Capillary leakage and congestion of gut mucosa epithelia cause watery gastrointestinal symptoms with occasional hematemesis, melena, or hematochezia. The ophthalmologic features of epidemic dropsy occur relatively late in the course of the disease. Ocular signs include increased ocular pressure and glaucoma from protein accumulation in the aqueous humor. Visual complications include subconjunctival hemorrhage, superficial
retinal hemorrhages, retinal venous dilatation and tortuosity, subhyaloid hemorrhages, macular and papillary edema, central retinal vein occlusion, visual field defects, and rarely permanent visual defects from optic nerve damage. In a case series of 230 documented cases of epidemic dropsy, the incidence of intraocular pressures exceeding 22 mmHg was about 11% with most elevations of intraocular pressure returning to normal values within 12 weeks. Inflammation of the anterior segment is usually absent.

Renal insufficiency with hypoalbuminemia and proteinuria may occur in serious cases of epidemic dropsy, resulting in acute renal failure. Bleeding occurs from sarcoidal lesions and telangiectasias on mucous membranes and gastrointestinal epithelial mucosa.\textsuperscript{106,107} Non-cardiogenic pulmonary edema and, rarely, cardiac failure develop in severe cases with hypoxemia, respiratory alkalosis, high-output cardiac failure, tachycardia, dyspnea, and increased $A-a$ gradient. Death results primarily from cardiac arrest secondary to congestive heart failure, noncardiogenic pulmonary edema, or pericardial fluid accumulation.\textsuperscript{108} Postmortem histological findings include venous congestion, extramedullary hematopoiesis, focal hemorrhages, proliferation of capillary endothelial cells, dilation of hepatic sinusoids, and monocellular infiltration of the central veins in the liver.\textsuperscript{86}

**DIAGNOSTIC TESTING**

**Analytical Methods**

During an epidemic, samples of adulterated mustard oil are screened for sanguinarine by the addition of ferric chloride to the sample.\textsuperscript{109} The appearance of a red-brown precipitate suggests the presence of $\geq 0.25\%$ argemone oil in the sample. The presence of sanguinarine in these samples is confirmed by HPLC with limits of detection in the range of 0.001$\%$ argemone oil in the sample.\textsuperscript{110}

**Biomarkers**

In a study of 45 patients with epidemic dropsy during an outbreak in New Delhi, sanguinarine was detected in eight urine samples collected within 2–3 weeks of onset of dropsy with concentrations ranging between 0.4 and 3.6$\mu$g/100mL. Three of 18 serum samples in the same group were positive for sanguinarine with concentrations of 1.2, 1.6, and 3.6$\mu$g/100mL.\textsuperscript{111}

**Abnormalities**

Epidemic dropsy patients typically have hypoalbuminemia, hypocalcemia, proteinuria, and azotemia, similar to nephrotic syndrome along with reduced concentrations of tocopherol and retinol secondary to depletion of antioxidants by reactive oxygen species.\textsuperscript{112} Chest x-ray may reveal signs of pulmonary edema and right ventricular cardiomegaly. Case series suggest that the dyspnea associated with epidemic dropsy usually results from a restrictive ventilatory defect with reduced carbon monoxide diffusing capacity rather than a cardiomyopathy.\textsuperscript{113} The electrocardiogram may demonstrate ST-T wave changes and premature ventricular contractions.\textsuperscript{96} Normochromic, normocytic anemia is a common finding despite expected hemoconcentration from intravascular fluid loss.\textsuperscript{107}

**TREATMENT**

Treatment for epidemic dropsy is supportive. Inpatient treatment includes compression stockings, protein-rich diet, correction of symptomatic hypocalcemia, and albumin infusions as indicated by the condition of the patient. Deficiencies in tocopherol and retinol may be corrected with supplementation, but there are inadequate clinical data to determine the clinical efficacy of the administration of antioxidants to patients with epidemic dropsy.\textsuperscript{114} Serial ophthalmologic examinations are necessary for several weeks to evaluate for the onset of glaucoma, which occurs in up to 11% of cases.\textsuperscript{115} Topical beta-receptor antagonists (timolol, levobunolol), alpha-receptor antagonists (brimonidine, iopidine) and parasympathetics (pilocarpine) may reduce intraocular pressures. Surgical intervention with trabeculectomy or laser trabeculoplasty may be necessary in severe cases. Patients should be followed for several weeks for signs of cardiac decompensation, cardiogenic and noncardiogenic pulmonary edema, and pericardial effusion. Diuretics and diuretics may improve the outcome of cardiovascular manifestations depending on the cause of reduced cardiac output (e.g., pericardial effusion or right-sided heart failure). Full recovery generally occurs within 3 weeks to 3 months, with a 5% mortality rate.\textsuperscript{116}

**EOSINOPHILIA-MYALGIA SYNDROME**

**HISTORY**

In 1980, Sternberg et al. reported a scleroderma-like illness with eosinophilia in a patient treated with L-5-
In the fall of 1989, the worldwide outbreak (United States, Canada, Germany, United Kingdom) of a disease with clinical features (eosinophilia, myalgias) similar to toxic oil syndrome appeared, primarily in the United States. This disease was subsequently called eosinophilia-myalgia syndrome. The first reported cases of myalgia and eosinophilia associated with L-tryptophan use occurred in three patients from New Mexico. The disease subsequently affected at least 1,500 people with about 30–40 deaths. Figure 1.4 displays the onset of cases of eosinophilia-myalgia syndrome during the 1989–1990 epidemic.

Typically, patients developed intense myalgias, peripheral eosinophilia, and dermatological lesions. The onset of eosinophilia-myalgia syndrome was associated mostly with the ingestion of contaminated L-tryptophan manufactured by a single Japanese manufacturer (Showa Denko K.K., Tokyo, Japan). Case reviews of patients who ingested L-tryptophan produced by other manufacturers (e.g., Optimax®, Merck & Co., Inc., Whitehouse Station, NJ) did not support the diagnosis of eosinophilia-myalgia syndrome in these patients. Since 1991, the current surveillance system has detected a few cases of nontryptophan-related cases of eosinophilic-myalgia syndrome now is similar to the rate before the 1989–1990 epidemic.

**EXPOSURE**

To date, analysis of case-associated L-tryptophan from Showa Denko revealed the following six contaminants: peak AAA, (undefined); peak E, (1,1′-ethylenebis[L-tryptophan]); peak 200, [2-(3-indolylmethyl)-L-tryptophan], peak C, (3a-hydroxy-1,2,3,3a,8,8a-hexahydropyrrolo-[2-3b]-indole-2-carboxylic acid); peak FF, [2-(2-hydroxy-indoline)-L-tryptophan]; and peak UV-5, [3-(N-phenylamino)-1,2-propanediol]. The concentrations of these compounds in the L-tryptophan preparations were very low, and these concentrations did not exceed purity specification for the United States Pharmacopeia. Analysis of aniline-contaminated rapeseed oil from the toxic oil syndrome suggested a possible link between toxic oil syndrome and eosinophilia-myalgia syndrome, based on the structural similarity between the latter contaminant [3-(N-phenylamino)-L-alanine] and 3-(N-phenylamino)-1,2-propanediol in contaminated rapeseed oil. Rodent studies indicate that metabolism of 3-(N-phenylamino)-1,2-propanediol...

---

produces 3-(N-phenylamino)-L-alanine. In vitro studies suggest that the biotransformation of 3-(N-phenylamino)-L-alanine by human liver microsomes produces a toxic metabolite (4-aminophenol) similar to the metabolism of the toxic biomarker (3-(N-phenylamino)-1,2-propanediol) associated with toxic oil syndrome. Potentially, the formation of this toxic metabolite causes the release of hazardous carbonyl species. However, animal studies have not reproduced eosinophilia-myalgia syndrome following administration of implicated tryptophan lots or case-associated contaminants (peak E, peak UV-5). Consequently, the identities of the responsible contaminant or contaminants remain unconfirmed. Isolated case reports have associated eosinophilia-myalgia syndrome with the ingestion of 5-hydroxytryptophan and lysine unrelated to the L-tryptophan associated with eosinophilia-myalgia syndrome. The inability to identify specific contaminants in cases of eosinophilia-myalgia syndrome and the lack of dose-response relationships between L-tryptophan and eosinophilia-myalgia syndrome suggests that the cause of eosinophilia-myalgia syndrome is multifactorial. The cause of eosinophilia-myalgia syndrome remains controversial.

Food Processing

The association of eosinophilia-myalgia syndrome with the ingestion of L-tryptophan from a single Japanese company suggests that contamination of the L-tryptophan products occurred during the fermentation process with genetically modified strains of Bacillus amyloliquefaciens. This manufacturer purified and isolated the tryptophan from the fermentation broth by using ion exchange resins followed by processing through an activated charcoal column prior to crystallization of the product. Before the epidemic of eosinophilia-myalgia syndrome, the fermentation and purification processes underwent several modifications including a reduction in the amount of activated charcoal and a change to B. amyloliquefaciens strain V.

DOSE RESPONSE

The risk of developing eosinophilia-myalgia syndrome increased with increased consumption of L-tryptophan Showa Denko products, suggesting a dose-response effect. In a cohort of 157 individuals from a psychiatric practice using Showa Denko L-tryptophan, the number of patients developing definite eosinophilia-myalgia syndrome increased from 13% in persons using 250 mg–1500 mg/daily to 50% in persons receiving >4000 mg/daily.

CLINICAL RESPONSE

Following the index cases of eosinophilia-myalgia syndrome in New Mexico, the US Centers for Disease Control (CDC) established a voluntary national surveillance system to monitor the course of eosinophilia-myalgia syndrome. The CDC defined a case of eosinophilia-myalgia syndrome as follows: 1) peripheral eosinophil count ≥1,000 cells/mm³, 2) generalized myalgias severe enough to disrupt the patient’s usual daily activities, and 3) absence of any infection or neoplasm that accounts for the patient’s symptoms. Based on this relatively specific case definition, two case-control studies linked the ingestion of Showa Denko L-tryptophan with the development of eosinophilia-myalgia syndrome. Although most authors accept the causal link between contaminated L-tryptophan and eosinophilia-myalgia syndrome, these studies have been criticized for methodological flaws including diagnostic, recall and reporting biases, bias in the inclusion and exclusion of cases and controls, inequalities between cases and controls, failure to ensure that L-tryptophan exposure preceded the illness, and failure to exclude other illnesses.

The onset of eosinophilia-myalgia syndrome occurs over days to weeks, primarily in Caucasian, middle-aged women. Clinical features associated with eosinophilia-myalgia syndrome include diffuse myalgias, fatigue, headache, skin lesions (peau d’orange, fasciitis, erythematous, maculopapular rash), sicca syndrome, and sensorimotor neuropathy. These effects are similar to, but less intense than the clinical features associated with the toxic oil syndrome. For most patients, the acute phase begins with the abrupt onset of intense myalgias and peripheral blood eosinophilia along with variable degrees of weakness, edema, cough, dyspnea, paresthesias, and induration. The fingers and toes are spared, and the myalgias and weakness typically involved the proximal muscles. After a few weeks to several months, a chronic phase develops, manifest by persistent myalgias, peripheral neuropathy, cognitive dysfunction, and varying degrees of dermal sclerosis. Follow-up studies of patients with eosinophilia-myalgia syndrome suggest that the number and severity of symptoms diminishes with time. Although most patients remain symptomatic, a few patients develop new symptoms one year after onset of the disease. Histological features of eosinophilia-myalgia syndrome include increased collagen deposition and perivascular accumulation of eosinophils, plasma cells, and lymphocytes in affected tissue. The differential diagnosis of eosinophilia-myalgia syndrome includes relatively rare diseases, such as eosinophilic myositis, Churg–Strauss syndrome, Loeffler’s syndrome, hypereosinophilic syndrome, eosinophilic gastroenteritis, and toxic oil syndrome.
PART 1 FOODBORNE and MICROBIAL TOXINS

DIAGNOSTIC TESTING

Analytical Methods

Methods to detect and quantify contaminants in l-tryptophan preparations include high performance liquid chromatography (HPLC), reversed phase HPLC (RP/HPLC), and RP/HPLC with online ultraviolet detection and mass spectrometry. The limit of detection of 1,1'-ethyldenebis(l-tryptophan) using RP/HPLC was 0.6 μg/g.

Biomarkers

Although at least six contaminants are associated with eosinophilia-myalgia syndrome, a specific contaminant responsible for eosinophilia-myalgia syndrome has not been identified. Therefore, to date there are no unique biomarkers for this disease.

Abnormalities

Case reports associated elevated serum aldolase, increased serum hepatic aminotransferases, and less frequently elevated serum creatine kinase concentrations with eosinophilia-myalgia syndrome. Antinuclear antibodies with a speckled pattern are occasionally detected. Marked peripheral eosinophilia may occur in the absence of symptoms.

TREATMENT

Treatment is supportive.

References

23. Lu YC, Wong PN. Dermatological, medical, and labora-
24. Fein GG, Jacobson JL, Jacobson SW, Schwartz PM, Dowler JK. Prenatal exposure to polychlorinated biphe-
25. Gladen BC, Rogan WJ. Decrement on six month and
one-year Bayley scores and prenatal polychlorinated bi-
G, Guo YL. The endocrine and reproductive function of
the female yu-cheng adolescents prenatally exposed to
27. Jacobson SW, Fein GG, Jacobson JL, Schwartz PM,
Dowler JK. The effect of intrauterine PCB exposure on
28. Rogan WJ, Gladen BC, Hung KL, Koong SL, Shih LY,
Taylor JS, et al. Congenital poisoning by polychlorinated
biphenyls and their contaminants in Taiwan. Science
29. Tsai PC, Ko YC, Huang W, Liu HS, Guo YL. Increased
liver and lung mortalities in 24-year follow-up of the
Taiwanese people highly exposed to polychlorinated
biphenyls and dibenzofurans. Sci Total Environ
2007;374:216–222.
30. Hori T, Tobishi K, Ashizuka Y, Nakagawa R, Todaka T,
Hirakawa H, Iida T. Congener specific determination of
PCBs in human blood using gel permeation chromatog-
raphy (GPC) and high resolution gas chromatography/
high resolution mass spectrometry (HRGC/HRMS).
31. Calaf RE, Pena J, Payutbi S, Blount BC, Posada de La
Paz M, Gelpi E, et al. Determination of aniline deriva-
tives in oils related to the toxic oil syndrome by atmos-
pheric pressure ionization-tandem mass spectrometry.
32. Chen PH, Luo ML, Wong CK, Chen CJ. Polychlorinated
biphenyls, dibenzofurans, and quaterphenyls in the toxic
rice-bran oil and PCBs in the blood of patients with
33. Nagayama J, Masuda Y, Kuratsune M. Determination of
polychlorinated dibenzo-furans in tissues of patients with
34. Lung S-C, Guo Y-L, Chang H-Y. Serum concentrations
and profiles of polychlorinated biphenyls in Taiwan Yu-
cheng victims twenty years after the incident. Environ
35. Ryan JJ, Levesque D, Panopio LG, Sun W, Masuda Y,
Kuroki H. Elimination of polychlorinated dibenzo-furans
(PCDFs) and polychlorinated biphenyls (PCBs) from
human blood in the yusho and yu-cheng rice oil poison-
36. Imamura T, Kanagawa Y, Matsumoto S, Tajima B, Uenot-
suchi T, Shibata S, Furue M. Relationship between
clinical features and blood levels of pentachlorodiben-
zofuran in patients with yusho. Environ Toxicol
37. Todaka T, Hirakawa H, Hori T, Tobishi K, Iida T, Furue
M. Concentrations of polychlorinated dibenzo-p-dioxins,
polychlorinated dibenzofurans, and non-ortho and mono-
ortho polychlorinated biphenyls in the blood of Yusho
38. Masuda Y, Yoshimura H. Polychlorinated biphenyls
and dibenzofurans in patients with yusho and their
toxicological significance: a review. Am J Ind Med
1984;5:31–44.
39. Posada de la Paz M, Philen RM, Abaitua Borda I. Toxic
oil syndrome: The perspective after 20 years. Epidemiol
40. Posada de la Paz M, Philen RM, Abaitua Borda I, Bernert
JT Jr, Gancedo JC, DuClos PJ, Kilbourne EM. Manufactur-
ing processes at two French rapeseed oil companies:
possible relationships to toxic oil syndrome in Spain.
41. Rigau-Perez JG, Perez-Alvarez L, Duenas-Castro S,
Choi K, Thacker SB, Germain JL, et al. Epidemiologic
investigation of an oil-associated pneumatic paralytic
esoinophilic syndrome in Spain. Am J Epidemiol
42. Posada M, Castro M, Kilbourne EM, Diaz de Rojas F,
Abaitua I, Tabuenca JM, et al. Toxic-oil syndrome: case
reports associated with the ITH oil refinery in Seville.
43. Reig N, Calaf RE, Meseguer A, Morató A, Escabros J,
Gelpí E, Abian J. LC-MS ion maps for the characteriza-
tion of aniline derivatives of fatty acids and triglycerides
in laboratory-denatured rapeseed oil. J Mass Spectrom
44. Hard GC. Short-term adverse effects in humans of
ingested mineral oils, their additives and possible
contaminants—a review. Hum Exp Toxicol 2000;19:
158–172.
45. Closa D, Folch E, Calaf RE, Abian J, Rosello-Catafau J,
Gelpí E. Absorption and effects of 3-(N-phenylamino)-
1,2-propanediol esters in relation to toxic oil syndrome.
46. Guiralt R, Norgaard L, Abaitua Borda I, Posada de la
Paz M, Abian J, Gelpi E. Pentachlorophenol and
pentachloroanisole in oil samples associated with the
toxic oil syndrome. Bull Environ Contam Toxicol
47. Morato A, Escabros J, Manich A, Reig N, Castano Y,
Abian J, Meseguer A. On the generation and outcome
of 3-(N-phenylamino)propane-1,2-diol derivatives in
denatured model oils related to toxic oil syndrome.
48. Ruiz-Mendez MV, Posada de la Paz M, Abian J, Calaf
RE, Blount B, Castro-Molero N, et al. Storage time and
deodorization temperature influence the formation of
aniline-derived compounds in denatured rapeseed oils.
PART 1 FOODBORNE and MICROBIAL TOXINS


75. Hayashi T, James TN. Immunohistochemical analysis of lymphocytes in postmortem study of the heart from fatal cases of the eosinophilia myalgia syndrome and of the toxic oil syndrome. Am Heart J 1994;127:1298–1308.


PART 1 FOODBORNE and MICROBIAL TOXINS


